phase chronic myeloid leukemia [AP-CML]) as confirmed by the presence of the BCR-ABL1 translocation [t(9;22) ] based on fluorescence in situ hybridization (FISH), cytogenetics, or quantitative reverse transcriptasepolymerase chain reaction (QRT-PCR); orFLT3/ITD+ AML with no prior treatment with a FLT3 TKI and 1) had failed to achieve morphologic complete remission (CR) or had relapsed after prior chemotherapy and was not a candidate for potentially curative treatment; or 2) was ≥ 60 years of age and not a candidate for standard induction chemotherapy. Subjects with CML had 1 of the following: a) T315I ABL1 mutation; b) known resistance to or intolerance of ≥ 2 TKIs with known efficacy (eg, imatinib, dasatinib, nilotinib) ; or c) resistance or intolerance to 1 TKI but was unable or unwilling to receive other TKIs of known efficacy. When enrollment into the CML Expansion Cohort was extended beyond the planned 15 subjects, only subjects with T315I(+) CP-CML were considered eligible.
3. The subject was ≥18 years old. 4. For CML, the subject had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. For AML, the subject had an ECOG performance status < 1. 5. The subject had adequate organ function as indicated by the following laboratory assessments performed within 14 days prior to the first dose of study drug:
• Hepatic: Serum bilirubin ≤ 1.5 times upper limit of normal (x ULN) unless due to leukemic involvement or Gilbert's syndrome (≤ 3 x ULN if due to leukemic involvement or Gilbert's syndrome); aspartate aminotransferase or alanine aminotransferase ≤ 2.5 x ULN (≤ 5.0 x ULN if due to leukemic involvement); alkaline phosphatase ≤ 2.5 x ULN unless due to leukemic involvement (≤ 5.0 x ULN if due to leukemic involvement).Renal: Serum creatinine ≤ 1.5 x ULN or 24 hour creatinine clearance ≥ 50 mL/min (subjects with a serum creatinine > 1.5 ULN were eligible if the 24 hour creatinine clearance was ≥ 50 mL/min).Female subjects of childbearing potential were required to have a negative serum or urine beta-human chorionic gonadotropin (β-hCG) pregnancy test within 14 days prior to the start of study drug. 7. Sexually active subjects who were fertile agreed to use an effective barrier method of contraception (eg, latex condom, diaphragm, or cervical cap) while on therapy and for 30 days following discontinuation of study drug. Nonfertile subjects or those not sexually active were also eligible. A nonfertile female was defined as one who was postmenopausal (amenorrheic for ≥ 12 months) or had undergone a tubal ligation, complete oophorectomy, or hysterectomy. A nonfertile male was defined as one who had undergone vasectomy.
8. The subject was capable of understanding and complying with the protocol and had signed the informed consent document (ICD).
Exclusion Criteria
Subjects who met any of the following criteria did not qualify for entry into the study:
1. For FLT3 AML, the subject had received prior treatment with a FLT3 TKI or had only extramedullary disease without bone marrow involvement.
2. The subject had received chemotherapy or a TKI ≤ 7 days, investigational agent ≤14 days, or radiotherapy ≤ 28 days prior to the start of study drug or had not recovered (to ≤ NCI-CTCAE v3.0 Grade 1 severity) from the acute toxicities associated with any prior treatments including approved therapies, investigational agents, and prior stem cell or bone marrow transplant. The following exceptions applied:
• Hydroxyurea was permitted at any time prior to study enrollment. Glucocorticoids (natural or synthetic) were allowed up to 48 hours prior to the start of study drug (with the exception of steroids for premedication and topical/nasal steroid use which were allowed at any time).The subject had BP-CML. (Note that subjects with BP-CML were eligible to participate in the dose escalation portion of the trial, but were not eligible for the expansion cohort.) 4. The subject had received immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus for graft-versus-host disease) ≤ 28 days prior to the first dose of study drug and had not recovered (to ≤ NCI-CTCAE v3.0 Grade 1 severity) from associated acute toxicities.
5. The subject had New York Heart Association class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or congestive heart failure.
6. Myocardial infarction within 3 months of the start of study drug.
7. The subject had an active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant.
8. The subject had any other severe concurrent disease and/or uncontrolled medical conditions, which, in the judgment of the investigator, could predispose subjects to unacceptable safety risks or compromise compliance with the protocol. 9. The subject was known to be positive for human immunodeficiency virus .
10. If female, the subject was pregnant or lactating.
11. The subject had a known allergy or hypersensitivity to any component of the investigational drug product. If a subject had more than 1 treatment-emergent adverse event that codes to the same preferred term, the subject was counted once for that preferred term a Preferred terms are sorted by descending frequency, as reported in the total column b Doses received in tablet form Musculoskeletal pain 4 (7.0%) 3 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 7 (12.3%) Myalgia 6 (10.5%) 1 (1.8%) 3 (5.3%) 0 (0.0%) 0 (0.0%) 10 (17.5%)
Pain in extremity 6 (10.5%) 3 (5.3%) 1 (1.8%) 1 (1.8%) 0 (0.0%) 11 (19.3%)
Nervous system disorders
19 (33.3%) 7 (12.3%) 4 (7.0%) 0 (0.0%) 0 (0.0%) 30 (52.6%) Hypoaesthesia 9 (15.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 9 (15.8%) Neuropathy peripheral 2 (3.5%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 3 (5.3%) Paraesthesia 9 (15.8%) 3 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 12 (21.1%) Peripheral sensory neuropathy 3 (5.3%) 1 (1.8%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 5 (8.8%) Cardiac disorders 6 (10.5%) 3 (5.3%) 4 (7.0%) 0 (0.0%) 2 (3.5%) 15 (26.3%) Cardiac failure congestive 1 (1.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (3.5%) 3 (5.3%)
Visual abnormalities 14 (24.6%) 5 (8.8%) 5 (8.8%) 0 (0.0%) 0 (0.0%) 24 (42.1%) Intraocular pressure increased 2 (3.5%) 1 (1.8%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 4 (7.0%)
Retinal vein occlusion 2 (3.5%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (5.3%)
Vision blurred 14 (24.6%) 2 (3.5%) 3 (5.3%) 0 (0.0%) 0 (0.0%) 19 (33.3%)
Visual impairment 3 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (5.3%) CML-CP 150 mg BID 1 5 (7) CHF AP = Accelerated phase; CP = Chronic phase; CHF = Congestive Heart Failure *None of the deaths were deemed related and were attributed to causes other than DCC-2036 # Listed in Table 3 as 'treatment-related AE' Figure S2 . Mean plasma rebastinib concentration-time profile following multiple dose administration of rebastinib PIC to steady state. Mean peak plasma concentrations of rebastinib were determined for individual patients receiving rebastinib as powder-in-capsule formulation at the indicated dose level, following at least one week of continuous dosing.
